Clinical use of AI based decision tools – is regulation needed? by Martin Hylleholt Sillesen
Fra Hanne Høy Kejser
views
Fra Hanne Høy Kejser
Short abstract
Every day, multiple different AI models focusing on clinical decision support are fielded for a vast array of medical use cases. While current regulatory requirements dictate a rigorous approval process for commercial models, home-grown models built from local research groups evade these restrictions.
This talk will provide a clinicians view of the pros and cons of fielding commercial vs. home grown models and discuss the need for a pathway to balance the often slow-moving and rigid regulatory approach vs. the currently unregulated expansion of home-grown models.
Bio
Dr. Martin Sillesen is a Danish General Surgeon, currently working at the Copenhagen University Hospital, Rigshospitalet, He graduated from the Univ. of Copenhagen Medical school in 2004, and obtained the PhD degree in medicine in 2014 from the same institution. He has worked in multiple different Danish hospitals and also completed a two-year research fellowship at the Massachusetts General Hospital/Harvard Medical School.
Currently, he is heading the Center for Surgical Translational and Artificial Intelligence Research at Rigshospitalet, a research group focusing on developing and testing new AI-enhanced approaches for clinical decision support and workflow optimization in the surgical setting. Concurrently, he has co-founded Aiomic, a healthtech company fielding AI-enhanced decision support and analytics frameworks for hospitals.